Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Type
- Observational
- Design
- Observational Model: OtherTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This trial is a single-center, prospective phase II clinical study, which mainly evaluates the efficacy and safety of first-line treatment with pembrolizumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma with PDL1 CPS?20 in China.
This trial is a single-center, prospective phase II clinical study, which mainly evaluates the efficacy and safety of first-line treatment with pembrolizumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma with PDL1 CPS?20 in China.
Tracking Information
- NCT #
- NCT04740996
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Yuankai Shi, MD Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Get Well Soon